Judith G Villablanca

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. pmc Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group
    Judith G Villablanca
    Children s Hospital Los Angeles, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California 90027, USA
    Clin Cancer Res 17:6858-66. 2011
  2. ncbi request reprint Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709)
    Judith G Villablanca
    Children s Hospital Los Angeles and the Department Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, USA
    J Clin Oncol 24:3423-30. 2006
  3. doi request reprint Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial
    Katherine K Matthay
    Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
    J Nucl Med 53:1155-63. 2012
  4. doi request reprint Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group
    Gregory A Yanik
    Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    J Nucl Med 54:541-8. 2013
  5. pmc Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study
    Katherine K Matthay
    Department of Pediatrics, University of California, San Francisco, 505 Parnassus, M647, San Francisco, CA 94143 0106, USA
    J Clin Oncol 27:1020-5. 2009
  6. ncbi request reprint Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study
    Katherine K Matthay
    Department of Pediatrics, University of California, San Francisco, School of Medicine, and UCSF Children s Hospital, San Francisco, CA 94143 0106, USA
    J Clin Oncol 24:500-6. 2006
  7. pmc Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma
    Alekist Quach
    Department of Pediatrics, UCSF Children s Hospital, University of California, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 56:191-201. 2011
  8. pmc Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group
    Julie R Park
    Department of Pediatrics, Children s Hospital and Regional Medical Center, University of Washington, Seattle, Washington 98105, USA
    Pediatr Blood Cancer 52:44-50. 2009
  9. doi request reprint Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143, USA
    Clin Cancer Res 18:2679-86. 2012
  10. ncbi request reprint The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma
    Araz Marachelian
    Department of Pediatrics, Children s Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, California, USA
    Pediatr Blood Cancer 58:675-81. 2012

Detail Information

Publications18

  1. pmc Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group
    Judith G Villablanca
    Children s Hospital Los Angeles, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California 90027, USA
    Clin Cancer Res 17:6858-66. 2011
    ..To determine the response rate to oral capsular fenretinide in children with recurrent or biopsy proven refractory high-risk neuroblastoma...
  2. ncbi request reprint Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709)
    Judith G Villablanca
    Children s Hospital Los Angeles and the Department Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, USA
    J Clin Oncol 24:3423-30. 2006
    ..To determine the maximal tolerated dosage (MTD) of oral fenretinide given as intact capsules for 7 days, repeated every 21 days, in children with high-risk solid tumors...
  3. doi request reprint Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial
    Katherine K Matthay
    Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
    J Nucl Med 53:1155-63. 2012
    ..Our aim was to establish the maximum tolerated dose of no-carrier-added (NCA) (131)I-MIBG, with secondary aims of assessing tumor and organ dosimetry and overall response...
  4. doi request reprint Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group
    Gregory A Yanik
    Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    J Nucl Med 54:541-8. 2013
    ..A semiquantitative mIBG score (Curie score [CS]) was assessed for utility as a prognostic indicator for a cohort of patients with high-risk metastatic disease...
  5. pmc Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study
    Katherine K Matthay
    Department of Pediatrics, University of California, San Francisco, 505 Parnassus, M647, San Francisco, CA 94143 0106, USA
    J Clin Oncol 27:1020-5. 2009
    ..The goal was to determine the maximum-tolerated dose of (131)I-MIBG in two consecutive infusions at a 2-week interval, supported by autologous stem-cell rescue (ASCR) 2 weeks after the second dose...
  6. ncbi request reprint Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study
    Katherine K Matthay
    Department of Pediatrics, University of California, San Francisco, School of Medicine, and UCSF Children s Hospital, San Francisco, CA 94143 0106, USA
    J Clin Oncol 24:500-6. 2006
    ..To determine the maximum-tolerated dose (MTD) and toxicity of iodine-131-metaiodobenzylguanidine ((131)I-MIBG) with carboplatin, etoposide, melphalan (CEM) and autologous stem-cell transplantation (ASCT) in refractory neuroblastoma...
  7. pmc Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma
    Alekist Quach
    Department of Pediatrics, UCSF Children s Hospital, University of California, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 56:191-201. 2011
    ..The aim of our study was to analyze the effects of (131) I-MIBG therapy on thyroid and liver function...
  8. pmc Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group
    Julie R Park
    Department of Pediatrics, Children s Hospital and Regional Medical Center, University of Washington, Seattle, Washington 98105, USA
    Pediatr Blood Cancer 52:44-50. 2009
    ..The components of therapy required for patients with INSS Stage 3 neuroblastoma and high-risk features remain controversial...
  9. doi request reprint Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143, USA
    Clin Cancer Res 18:2679-86. 2012
    ..Irinotecan is a known radiosensitizer with activity in neuroblastoma. This phase I study aimed to determine the recommended phase 2 dose of MIBG together with fixed doses of vincristine and irinotecan...
  10. ncbi request reprint The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma
    Araz Marachelian
    Department of Pediatrics, Children s Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, California, USA
    Pediatr Blood Cancer 58:675-81. 2012
    ..To describe the serial histopathology of intermediate risk stage 3 neuroblastoma after chemotherapy, and correlate with residual mass at therapy completion and outcome...
  11. ncbi request reprint Successful multimodality therapy of recurrent multifocal juvenile granulosa cell tumor of the ovary
    Anat Erdreich-Epstein
    Department of Pediatrics, Childrens Hospital Los Angeles, Keck School of Medicine, California 90027, USA
    J Pediatr Hematol Oncol 24:229-33. 2002
    ..She tolerated therapy well and is in complete remission 69 months after her recurrence...
  12. doi request reprint Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation
    Soumen Khatua
    Neural Tumors Program, Center for Cancer and Blood Diseases, Childrens Hospital Los Angeles, Los Angeles, California, USA
    Pediatr Blood Cancer 55:42-6. 2010
    ..The purpose of this study was to evaluate a reduced irradiation dose strategy for newly diagnosed primary central nervous system (CNS) germinomas...
  13. doi request reprint Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010
    Alexa E Gozali
    Children s Center for Cancer and Blood Diseases, Children s Hospital, Los Angeles, CA, USA
    Pediatr Blood Cancer 58:905-9. 2012
    ..We have investigated the clinical features and overall survival of all CPT patients treated at Children's Hospital Los Angeles (CHLA) over a 20-year period, with particular attention to the association of CPT with LFS...
  14. ncbi request reprint Retinoid therapy of high-risk neuroblastoma
    C Patrick Reynolds
    Division of Hematology Oncology, Children s Hospital of Los Angeles and the University of Southern California Keck School of Medicine, Los Angeles, CA 90054, USA
    Cancer Lett 197:185-92. 2003
    ..Thus, further clinical trials of 4-HPR in neuroblastoma, and of 4-HPR in combination with ceramide modulators, are warranted...
  15. pmc Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma
    Shahab Asgharzadeh
    Children s Hospital Los Angeles, Los Angeles, CA 90027, USA
    J Clin Oncol 30:3525-32. 2012
    ..In this study, we investigated the hypothesis that expression of genes related to tumor-associated inflammatory cells correlates with the observed differences in survival by age at diagnosis and contributes to a prognostic signature...
  16. ncbi request reprint Approaches to treatment for extraocular retinoblastoma: Children's Hospital Los Angeles experience
    Rima F Jubran
    Department of Pediatrics, University of Southern California Keck School of Medicine and Children s Hospital Los Angeles, Los Angeles California, USA
    J Pediatr Hematol Oncol 26:31-4. 2004
    ..Patients with extraocular retinoblastoma who achieve remission may benefit from consolidation of their therapy with autologous bone marrow transplant...
  17. ncbi request reprint A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas
    Roger J Packer
    Center for Neuroscience and Behavioral Medicine, Division of Neurology, Children s National Medical Center, Washington, DC 20010, USA
    Cancer 104:1968-74. 2005
    ..The objective of this Phase I study was to determine the toxicity and feasibility of delivering RMP-7 and carboplatin for 5 successive days during radiotherapy to children with newly diagnosed, diffuse, intrinsic brainstem gliomas...
  18. ncbi request reprint Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas
    Roger J Packer
    Division of Neurology, Children s National Medical Center, Washington, DC 20010, USA
    Cancer 104:1281-7. 2005
    ..The goal of the current Phase I study was to determine the toxicity and feasibility of delivering RMP-7 and carboplatin for 5 successive days during radiotherapy...